Oramed Pharmaceuticals Inc.
Seite 38 von 40 Neuester Beitrag: 21.05.23 08:11 | ||||
Eröffnet am: | 28.03.07 13:46 | von: OttomanRos. | Anzahl Beiträge: | 988 |
Neuester Beitrag: | 21.05.23 08:11 | von: Jürgen1964 | Leser gesamt: | 259.342 |
Forum: | Hot-Stocks | Leser heute: | 118 | |
Bewertet mit: | ||||
Seite: < 1 | ... | 34 | 35 | 36 | 37 | | 39 | 40 > |
Screenshot aus Yahoo Finance
https://finance.yahoo.com/quote/ORMP?p=ORMP&.tsrc=fin-srch
Phase 3 Oral Insulin (ORMD-0801) Trials for the Treatment of Type 2 Diabetes: Over 75% Enrollment Completed
Upcoming Milestones:
6-month topline efficacy results from larger ORA-D-013-1 trial expected in 2022
ORA-D-013-2 trial expected to complete enrollment in 2022
Oravax Medical, Inc.: Oral COVID-19 Vaccine
Upcoming Milestones:
Topline data from Phase 1 expected H1 2022
Initiation of Phase 2/3 oral COVID-19 vaccine trials expected H2 2022
Phase 2 NASH Trial: 50% Enrollment Completed
Upcoming Milestones:
Enrollment completion expected H1 2022
Topline data expected in H2 2022
Oral GLP-1
Upcoming Milestone:
Bioavailability (PK and PD) expected in H1 2022
https://www.oramed.com/oramed-issues-annual-message-to-shareholders/
Oramed’s Diabetes Market Survey Shows Strong Interest for ORMD-0801 Oral Insulin Candidate Among Physicians
– 76 Percent of the Physicians Responded They “Definitely Would” or “Probably Would” Prescribe Oramed’s Oral Insulin Candidate for Type 2 Diabetes Patients
zu #936
Eine KE dürfte auch bald ins Haus stehen.
Date: Wednesday, May 25, 2022
Location: Fontainebleau Miami Beach Hotel, Miami, Florida